{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:01:03Z","timestamp":1789624863363,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"DOI":"10.1007\/s00392-026-02970-y","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:04:09Z","timestamp":1781676249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative cardiovascular outcomes of GLP-1 receptor agonists vs. SGLT2 inhibitors in type 2 diabetes: a large-scale real-world cohort analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5575-4208","authenticated-orcid":false,"given":"Kohei","family":"Ukita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schmelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland Richard","family":"Tilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2970_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH (2018) Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol 17:83","journal-title":"Cardiovasc Diabetol"},{"key":"2970_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-019-0983-1","volume":"19","author":"S Seyed Ahmadi","year":"2020","unstructured":"Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M (2020) Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol 19:9","journal-title":"Cardiovasc Diabetol"},{"key":"2970_CR3","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44:4043\u20134140","journal-title":"Eur Heart J"},{"key":"2970_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 6:148\u2013158","journal-title":"JAMA Cardiol"},{"key":"2970_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12902-022-01036-0","volume":"22","author":"J Qin","year":"2022","unstructured":"Qin J, Song L (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC Endocr Disord 22:125","journal-title":"BMC Endocr Disord"},{"key":"2970_CR6","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Fletcher RA, Heath L, Perkovic A, Vaduganathan M, Badve SV et al (2024) Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation 150:1781\u20131790","journal-title":"Circulation"},{"key":"2970_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0326534","volume":"20","author":"AC Li","year":"2025","unstructured":"Li AC, Lin YC, Huang JY, Chen LC, Chua SK (2025) Superior cardiovascular protection with GLP-1 RAs over SGLT2 inhibitors in DM and HFpEF: a propensity score matching study. PLoS ONE 20:e0326534","journal-title":"PLoS ONE"},{"key":"2970_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008","journal-title":"N Engl J Med"},{"key":"2970_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424","journal-title":"N Engl J Med"},{"key":"2970_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461","journal-title":"N Engl J Med"},{"key":"2970_CR11","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098","journal-title":"N Engl J Med"},{"key":"2970_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","volume":"74","author":"A Wang","year":"2019","unstructured":"Wang A, Green JB, Halperin JL, Piccini JP Sr (2019) Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol 74:1107\u20131115","journal-title":"J Am Coll Cardiol"},{"key":"2970_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4239\/wjd.v14.i5.512","volume":"14","author":"M Leopoulou","year":"2023","unstructured":"Leopoulou M, Theofilis P, Kordalis A, Papageorgiou N, Sagris M, Oikonomou E et al (2023) Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment. World J Diabetes 14:512\u2013527","journal-title":"World J Diabetes"},{"key":"2970_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","volume":"31","author":"HD Zhang","year":"2024","unstructured":"Zhang HD, Ding L, Mi LJ, Zhang AK, Zhang K, Jiang ZH et al (2024) Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis. Eur J Prev Cardiol 31:770\u2013779","journal-title":"Eur J Prev Cardiol"},{"key":"2970_CR15","doi-asserted-by":"publisher","first-page":"204201882312223","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH (2024) Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab 15:20420188231222370","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2970_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9:234","journal-title":"Signal Transduct Target Ther"},{"key":"2970_CR17","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacbts.2023.01.005","volume":"8","author":"LJ Bohne","year":"2023","unstructured":"Bohne LJ, Jansen HJ, Dorey TW, Daniel IM, Jamieson KL, Belke DD et al (2023) Glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice. JACC Basic Transl Sci 8:922\u2013936","journal-title":"JACC Basic Transl Sci"},{"key":"2970_CR18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134:752\u2013772","journal-title":"Circulation"},{"key":"2970_CR19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/17474930241253988","volume":"19","author":"A Adamou","year":"2024","unstructured":"Adamou A, Barkas F, Milionis H, Ntaios G (2024) Glucagon-like peptide-1 receptor agonists and stroke: a systematic review and meta-analysis of cardiovascular outcome trials. Int J Stroke 19:876\u2013887","journal-title":"Int J Stroke"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02970-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02970-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02970-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:04:10Z","timestamp":1781676250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02970-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":19,"alternative-id":["2970"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02970-y","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.R.T. has received honoraria for lectures from Pfizer, Abbott, Biosense Webster, Boston Scientific, Doctrina Med, cme4u, Medtronic, Radcliff Cardiology, and Wikonect. He has received honoraria for advisory board participation and consulting from Boston Scientific, Biosense Webster, Capvision, Guidepoint, Haemonetics, Medtronic, Philips, and Abbott. His institution has received research funding or participated in clinical trials sponsored by Biotronik, Abbott, Boston Scientific, Medtronic, Lifetech, and Johnson & Johnson. He has also received travel grants from Biosense Webster, Abbott, Boston Scientific, Medtronic, and Philips.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}